Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials

Open access
Whitley, Jill, Zwolinski, Christopher, Denis, Christian, Maughan, Maureen, Hayles, Leonie, Clarke, David, Snare, Meghan, Liao, Hong, Chiou, Sean, Marmura, Tina, Zoeller, Holly, Hudson, Ben, Peart, John, Johnson, Monica, Karlsson, Amelia, Wang, Yunfei, Nagle, Cynthia, Harris, Cherell, Tonkin, Daniel, Fraser, Stephanie, Capiz, Lieza, Zeno, Christina L., Meli, Yvonne, Martik, Diana, Ozaki, Daniel A., Caparoni, Amy, Dickens, Jason E., Weissman, Drew, Saunders, Kevin O., Haynes, Barton F., Sempowski, Gregory D., Denny, Thomas N., Johnson, Matthew R. · 2022 · Translational Research

Abstract

The remarkable success of SARS CoV-2 mRNA-based vaccines and the ensuing interest in mRNA vaccines and therapeutics have highlighted the need for a scalable clinical-enabling manufacturing process to produce such products, and robust analytical methods to demonstrate safety, potency, and purity. To date, production processes have either not been disclosed or are bench-scale in nature and cannot be readily adapted to clinical and commercial scale production. To address these needs, we have advanced an aqueous-based scalable process that is readily adaptable to GMP-compliant manufacturing, and developed the required analytical methods for product characterization, quality control release, and stability testing. We also have demonstrated the products produced at manufacturing scale under such approaches display good potency and protection in relevant animal models with mRNA products encoding both vaccine immunogens and antibodies. Finally, we discuss continued challenges in raw material identification, sourcing and supply, and the cold chain requirements for mRNA therapeutic and vaccine products. While ultimate solutions have yet to be elucidated, we discuss approaches that can be taken that are aligned with regulatory guidance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trsl.2021.11.009

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 176

Metadata

Authors
Whitley, J., Zwolinski, C., Denis, C., Maughan, M., Hayles, L., Clarke, D., Snare, M., Liao, H., Chiou, S., Marmura, T., Zoeller, H., Hudson, B., Peart, J., Johnson, M., Karlsson, A., Wang, Y., Nagle, C., Harris, C., Tonkin, D., Fraser, S., Capiz, L., Zeno, C. L., Meli, Y., Martik, D., Ozaki, D. A., Caparoni, A., Dickens, J. E., Weissman, D., Saunders, K. O., Haynes, B. F., Sempowski, G. D., Denny, T. N., & Johnson, M. R.
Venue
Translational Research
Publisher
Elsevier BV
Published
2022-04
Volume
242
Pages
38-55
ISSN
  • 1878-1810 (ISSN-L)
  • 1931-5244
OpenAlex
W4200021428
Cited by
176
References
14
FWCI
5.10
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. https://app.cochat.ai/papers/10.1016/j.trsl.2021.11.009
The paper
Whitley, J., Zwolinski, C., Denis, C., Maughan, M., Hayles, L., Clarke, D., Snare, M., Liao, H., Chiou, S., Marmura, T., Zoeller, H., Hudson, B., Peart, J., Johnson, M., Karlsson, A., Wang, Y., Nagle, C., Harris, C., Tonkin, D., . . . Johnson, M. R. (2022). Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Translational Research. https://doi.org/10.1016/j.trsl.2021.11.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.